Novonesis
biological solutions for sustainability
- B2B
About Novonesis
development and application of enzyme-based and microbial biosolutions to enhance sustainability across nutrition, biofuel, and resource efficiency sectors worldwide
Key facts
- Industry
- Biotechnology Research
- Company size
- 10,000+ employees
- Revenue
- €4.2BFY2025, publicly reported
- Website
- novonesis.com
- linkedin.com/company/novonesis
Novonesis in the news
- Novonesis' bid for Microbiogen under review in Australia
Australia's competition watchdog is reviewing Novonesis' proposed acquisition of Microbiogen.
- SEB raises Novonesis price target to 560 Danish kroner (545), reiterates buy
SEB increased Novonesis's price target to 560 Danish kroner and reiterated its buy rating.
- Efficiency and sustainability go hand in hand in modern poultry production | Novonesis
Novonesis's Dr. Steve Lerner explains how improving feed efficiency, gut health, and microbiome management can enhance poultry production efficiency and sustainability.
- Novonesis raises 2026 outlook as first-half sales jump 8%
Novonesis increased its 2026 outlook due to an 8% jump in first-half sales, alongside announcing a EUR 1 billion share buyback program and acquiring the remaining 77% of MicroBioGen.
- Novonesis shares jump 9% after Q2 beat, raised 2026 sales guidance, buyback
Novonesis shares jumped 9% due to strong Q2 results, raised 2026 sales guidance, and the announcement of a —1 billion share buyback program.
Novonesis at a glance
Novonesis is a B2B company in the Biotechnology Research industry.
Novonesis has 10,000+ employees.
Novonesis's revenue is €4.2B (FY2025, publicly reported).
Selling to companies like Novonesis?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies